论文部分内容阅读
1983年,Waddell和Loughry首次报道,苏灵达(sulindac)使4例家族性腺瘤性息肉病(familialadenomatosis polyposis,FAP)患者直肠腺瘤性息肉消退。近10年来,一些动物癌发生模型应用非类固醇抗炎药(nonsteroid anti-infla-m matory drugs,NSAIDS)治疗的结果支持上述的报道。而且,一些病例报告和有关人的对照性研究也证实NSAIDS可使腺瘤消退,虽然有几种假说已取得了某些进展,但NSAIDS化学预防结直肠癌的机制迄今尚未完全阐明。1 家族性腺瘤性息肉病 结直肠腺瘤消退主要在FAP患者中得到证实。FAP及一常
In 1983, Waddell and Loughry first reported that sulindac regressed the adenoma polyps in 4 patients with familial adenomatosis polyposis (FAP). In the past decade, the results of some animal models of carcinogenesis using nonsteroidal anti-inflamatomics (NSAIDS) support the above report. Moreover, some case reports and studies on human controls have also confirmed that NSAIDS regresses adenomas. Although there are several hypotheses that have made some progress, the mechanism by which NSAIDs chemopreventively prevent colorectal cancer has not yet been fully elucidated. 1 familial adenomatous polyposis Colorectal adenoma regression was mainly confirmed in FAP patients. FAP and a regular